WILEX AG - improved financial outlook due to cost optimization

Munich, 12 July 2007. The Munich-based biopharmaceutical company WILEX AG (ISIN DE0006614720/Frankfurt Stock Exchange/Prime Standard) revises its financial guidance for 2007 due to optimization of the programme for production of RENCAREX®* consistency lots and due to higher than anticipated patient randomisation in countries with lower costs. The Company expects to reduce expenses in the financial year 2007 by approximately 12 % below the original budget. Assuming a planned project progress and without additional cash inflow the available liquidity of WILEX will probably reach until the first quarter of 2009 which is beyond the previously published forecast of the second half of 2008.

Contact
Juliane Giese
Manager Public Relations
WILEX AG
Grillparzerstr. 10
81675 München
Germany
Tel.: +49 (0)89-41 31 38-29
Fax: +49 (0)89-41 31 38-99
Email: investors@wilex.com
Website: http://www.wilex.com

This communication contains certain forward-looking statements, relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by general discussion of strategy, plans or intentions of the Company. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.


Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.